IPAC date: May of 13
|
|
- Homer Marsh
- 5 years ago
- Views:
Transcription
1 National Institute for Health and Care Excellence IP685/3 Transcatheter aortic valve implantation (transcatheter aortic valve replacement) for aortic stenosis Consultation Comments table IPAC date: May of 13
2 1 Consultee 1, 6 Sec Comments Response 1.1 The (draft) recommendations in section 1 are the most important part of this document. They need to be as clear as possible and consistent with the evidence base for TAVI. The most important of all of the recommendations would seem to be the group of patients for whom TAVI should be considered. While there is a statement on page 1 in the introduction that TAVI may be an alternative to surgical aortic valve replacement in patients for whom conventional valve replacement is not suitable, or who are at high risk of serious complications, there is no recommendation in the body of the text which specifies, either in general or more specific terms, when TAVI is indicated or should be considered. This appears to be an important omission. TAVI for aortic stenosis was given standard arrangements leaving it to the multidisciplinary team to determine the level of risk for each patient. Therefore the committee decided not to change 1.1 in the guidance. A committee comment has been added to section 6 in the guidance to indicate that TAVI is a potential treatment for patients who would not otherwise be suitable for surgical aortic valve replacement 2 Consultee 2 Manufacturer Boston Scientific We recommend that consideration is given to amending recommendation 1.1 so that it includes reference to the indications for TAVI that are supported by the evidence base. For example, "Current evidence on the safety and efficacy of transcatheter aortic valve implantation (TAVI) for aortic stenosis is adequate to support the use of this procedure...in patients who are not suitable for surgical AVR or who are at high risk for surgical AVR...provided that standard arrangements are in place for clinical governance, consent and audit." 1-6 Boston Scientific support all of the recommendations and the document. Consultee agrees with the recommendations. 2 of 13
3 3 Consultee 3 Manufacturer Medtronic 4 Consultee 1 NHS professional 5 Consultee 1, 6 Sec Comments Response 1 and general Thank you for the opportunity to provide comments. Given the substantive clinical evidence for high, intermediate and low risk patients, Medtronic support the decision to upgrade the IPG from "special" to "standard arrangements" for clinical governance, consent and audit. We wish to highlight that the longer term evidence available is for earlier generation TAVI devices and so it may be useful for the reader to understand that some newer TAVI devices are showing promise in terms of improved outcomes such as mortality, Stroke, paravalvular leak, major vascular complications and need for pacemaker. 1.3 We don't have a cardiac anaesthetist in the MDT, and I do not think it is a good use of their time - in a centre where TF procedures are done under local anaesthetic. Suggest re-word 1.3? Perhaps - 'the opinion of a cardiac anaesthetist should be available where necessary'. 1.3 The opinion of a cardiac anaesthetist is not required for all patients being considered for TAVI and will only be required for a minority of cases in centres where TAVI is undertaken under local anaesthetic (with or without sedation). Certainly a cardiac anaesthetic opinion should be available when required but anaesthetic attendance at TAVI MDTs should not be mandatory. This should be reflected in section 1.3. Consultee agrees with the recommendations. IPAC added a comment in section 6 as follows: the longer-term evidence on TAVI is from earlier generation TAVI devices and the technology is evolving. IPAC amended1.3 as follows: Patient selection should be carried out by an experienced multidisciplinary team, which must include interventional cardiologists experienced in the procedure, cardiac surgeons, an expert in cardiac imaging and when appropriate, a cardiac anaesthetist and a specialist in elderly medicine. The multidisciplinary team should determine the risk level for each patient and the TAVI device most suitable for them. See response to comment 4. 3 of 13
4 6 Consultee 7 Independent consultancy Health Economics & Outcomes Research General, 1.3,1.4 We are pleased that the IPG on TAVI has been updated some 5 years after the previous version but we have concerns that some of the comments in the recommendation are sensitive to the currently reviewed data. If there is another 5 years before this procedure guidance is updated again then some of the statements may be inappropriate. For example, 1.4 During the consent process patients should be told about all alternative treatment options and that there is currently a lack of information on the longer-term efficacy of TAVI. The first TAVI procedures were performed in 2002 and commercial products launched in Although these were in relatively small numbers there are already potentially up to 15 years follow up available in addition to 5 year RCT follow up and almost 10 years from national registries. Although we conceded that this is not comparable with the experience in surgical aortic valve replacement there are many new surgical valves being implanted now also without this level of long-term efficacy data, for which there is no specific warning recommendation. Given the elderly nature of most TAVI patients we feel this comment should be placed into context and at the very least reworded to state something like During the consent process patients should be told about all alternative treatment options, their advantages and disadvantages and any limitations on currently available data, for example on durability. IPAC amended 1.4 as follows: During the consent process patients should be told about all treatment options and their advantages and disadvantages. Also the recommendation does not provide clinicians with information on the alternative TAVI devices available. Therefore we would suggest that an additional statement that the choice of IPAC amended 1.3 as follows: 4 of 13
5 7 Consultee 4 NHS professional Sec Comments Response device depends on the clinical decision making process and appropriate risk-benefit assessment. For example: Patient selection should be carried out by an experienced multidisciplinary team, which must include interventional cardiologists experienced in the procedure, cardiac surgeons, a cardiac anaesthetist and an expert in cardiac imaging. The multidisciplinary team should determine the risk level for each patient and the TAVI device most suitable for that patient The current document only states the need for a multi-disciplinary team including both cardiology and cardiac surgeons for the patient selection process for TAVI, and does not make any recommendation in regard to the procedure and post-operative care. The recent USA - STS publication highlighted the USA experience where the multi-disciplinary involvement continued in both the intra-operative technical aspects and post operatively, with involvement of both cardiology and cardiac surgeons throughout in three quarters of procedures. Patient selection should be carried out by an experienced multidisciplinary team, which must include interventional cardiologists experienced in the procedure, cardiac surgeons, an expert in cardiac imaging, and when appropriate, a cardiac anaesthetist and a specialist in elderly medicine. The multidisciplinary team should determine the risk level for each patient and the TAVI device most suitable for them. Thank you for your comments. IPAC amended 1.5 as follows. TAVI is a technically challenging procedure that should only be done in specialised centres and only by clinicians and teams with special training and experience in complex endovascular interventions. Units doing this procedure should have both cardiac and vascular surgical support for the emergency treatment of complications and subsequent patient care. If the role of the cardiac surgeon in the UK becomes merely a perfunctary formality for selection only, then continued engagement of cardiac surgeons will disappear. 5 of 13
6 8 Consultee 5 Relative/Representative of patient Sec Comments Response 1.4 Suggest to make wording of section 1.4 regarding uncertainty a little more SMART, by including a specific time-related component that is supported by evidence. Please incorporate into section 1.4 relevant text from section 6.4 which states that "there is a lack of evidence after 5 years followup". IPAC amended 1.4 as follows: During the consent process patients should be told about all treatment options and their advantages and disadvantages. 9 Consultee 1, 6 Please see my suggested change to Section 1.4 below as presented in parentheses at the end of the section: During the consent process patients should be told about all alternative treatment options and that there is currently a lack of information on the longer-term efficacy of TAVI (beyond 5 years follow-up). 2 This section is entitled "indications and current treatments" but it includes no reference at all to TAVI. Either the title should be modified so that it reflects what is included in this section (mostly comment about surgical AVR) or the indications for TAVI should be included in this section. IPAC amended section 2 in the guidance. 6 of 13
7 10 Consultee 1, 6 Sec Comments Response 2.1 There is little or no reference in the document to the poor prognosis of symptomatic severe aortic stenosis. It would be worth considering modifying section 2.1 through the addition of a statement which describes the poor prognosis since this is one of the main reasons for treating this group of patients. IPAC amended section 2.1 in the guidance. For example: 2.1 Aortic stenosis causes impaired outflow of blood from the heart and is usually progressive. The increased cardiac workload leads to left ventricular hypertrophy and heart failure. Symptoms of aortic stenosis typically include shortness of breath and chest pain on exertion. Mortality rates are high in symptomatic patients. 11 Consultee 1, Aortic balloon valvuloplasty is rarely, if ever, a definitive treatment for aortic stenosis. Consider modifying the final sentence of section 2.2 to "Aortic balloon valvuloplasty is occasionally used...as bridging or palliative treatment." IPAC amended section 2.2 in the guidance. 7 of 13
8 12 Consultee 1, 6 2 The second sentence in section 2.3 seems out of place ("Patients for whom SAVR is suitable range from those considered to be high risk (for example, as defined in the PARTNER 1A trial) to those for whom the benefits of surgery clearly outweigh the risks of surgery.") It may be more logical to reorder some of the statements in section 2 so that the indications for surgical AVR come before the potential contraindications to surgical AVR, to change the statement about patients who are suitable for surgical AVR so that the most clear-cut (low risk) patients are mentioned first, and to conclude with a statement that it is these high risk patients who should be considered for TAVI. For example: IPAC amend section 2 in the guidance. 2.1 Aortic stenosis causes impaired outflow of blood from the heart and is usually progressive. The increased cardiac workload leads to left ventricular hypertrophy and heart failure. Symptoms of aortic stenosis typically include shortness of breath and chest pain on exertion. Mortality is high in patients with symptomatic aortic stenosis. 2.2 Surgical aortic valve replacement (SAVR) with an artificial (biological or mechanical) prosthesis is the conventional treatment for patients with severe symptomatic aortic stenosis who are well enough for surgery. Optimal medical care has traditionally been the only option for those whose condition is unsuitable for surgery. Aortic balloon valvuloplasty is occasionally used as bridging or palliative treatment. 8 of 13
9 Sec Comments Response 2.3 Patients for whom SAVR may be suitable range from those in whom the benefits of surgery clearly outweigh the risks of surgery to those considered to be at high risk for surgery (for example, as defined in the PARTNER 1A trial). 13 Consultee 1, 6 14 Consultee 1 NHS professional 15 Consultee 1 NHS professional 2.4 SAVR may not be suitable for patients because of medical comorbidities or technical considerations (for example, if the patient has a calcified aorta or scarring from previous cardiac surgery), which mean that the risks of SAVR outweigh the potential benefits. This is the group of patients who should be considered for TAVI. 3.1 An important benefit of TAVI compared with surgical AVR is the avoidance of sternotomy. It would be sensible to modify section 3.1 so that it reads, Transcatheter aortic valve implantation (TAVI) aims to provide a less invasive alternative to open cardiac surgery for treating aortic stenosis, avoiding the need for sternotomy and cardiopulmonary bypass. 3.2 Increasingly procedures are undertaken with local anaesthetic alone. Suggest reword 3.2. Perhaps '... local anaesthesia with or without sedation'. 3.2 Most (?all) UK centres will be over 90% TF. I would have thought section 3.2 should at least state that most cases are undertaken via the transfemoral route. 9 of 13 IPAC amended section 3.1 in the guidance. Section 6.2 states that there is a move towards using sedation rather than general anaesthesia for this procedure. IPAC amended 3.2 as follows: TAVI may be done with the patient under general anaesthesia or using local anaesthesia with or without sedation IPAC reworded section 3.2 to reflect this and dispensed the committee comment in section 6in the guidance.
10 16 Consultee 6 17 Consultee 8 Manufacturer- St Jude Medical 18 Consultee 7 Independent consultancy Health Economics & Outcomes Research Sec Comments Response 3.3 Predilatation is now undertaken in a minority of TAVI cases. It might therefore be sensible to reword section 3.3. For example, Valve implantation may be preceded by balloon dilatation, depending on valve anatomy, prosthesis type and institutional preference. 1, 3.3 We think that the draft guidance looks very good and the focus on the MDT for patient selection is a very important point. The only comment we would make, if it is not too late, is a minor one relating to the description of the procedure and section 3.3. The new prosthetic valve is inserted inside the native diseased valve and not over it. It may be a matter of interpretation on description, that s all. 3.3 Although balloon pre-dilation of the aortic valve before TAVI is used widely the clinical practice is evolving. We suggest changing the wording of this slightly to reflect the contemporary reports, e.g. Initially the aortic valve ring may be dilated using a balloon catheter, which is advanced over a guidewire. The new prosthetic valve is manipulated into position and used over the existing aortic valve. IPAC amended 3.3 as follows: Initially the aortic valve ring may be dilated using a balloon catheter, which is advanced over a guidewire. The new prosthetic valve is manipulated into position and inserted inside the existing aortic valve. IPAC amended 3.3 as follows: Initially the aortic valve ring may be dilated using a balloon catheter, which is advanced over a guidewire. The new prosthetic valve is manipulated into position and inserted inside the existing aortic valve. IPAC amended section 3.3 as follows: Initially the aortic valve ring may be dilated using a balloon catheter, which is advanced over a guidewire. The new prosthetic valve is manipulated into position and inserted inside the existing aortic valve. 19 Consultee 7 Independent consultancy Health Economics & Outcomes Research 3.4 All commercially available TAVI devices in the UK contain animal derived material. 10 of 13 IPAC amended 3.4 as follows Different devices are available for this procedure and contain material derived from animal sources.
11 20 Consultee 3 Manufacturer Medtronic 21 Consultee 7 Independent consultancy Health Economics & Outcomes Research Sec Comments Response 6.1 Section 6.1 states that the risk of needing a permanent pacemaker implanted after the procedure is influenced by the technique and by the type of valve used. It is important to highlight here that other key outcome measures (mortality, Stroke, paravalvular leak, major vascular complications) are also influenced by the technique and type of valve used. 6.1 The difference in the incidence of permanent pacemaker following TAVI is known to differ between devices. The difference in absolute incidence of other complications and procedural factors such as vascular complications, need for post-dilatation, etc. are also known and influence the clinical decision making for the selection of the most appropriate device. There should be an acknowledgement that the MDT decision on TAVI also encompasses the access route and device selection for optimal patient outcome. IPAC amended 6.1 as follows The risk of needing a permanent pacemaker and other complications after the procedure depends on the technique and the type of valve used. Thank you for your comments. IPAC amended 6.1 as follows. The risk of needing a permanent pacemaker and other complications after the procedure depends on the technique and the type of valve used. 11 of 13
12 22 Consultee 4 NHS professional 6.4 This document, apart from a single mention in regard to the paucity of evidence beyond 5 years, has made no attempt to investigate/advice on the current expected longevity of TAVI bioprosthetic valves. There is a wealth of data on the expected durability of current surgically implanted bioprosthetic valves that can be used for comparative purposes, as well as the importance of specific manufacturing processes such as anticalcification agents/processes, and importance of patient age. The European & USA guidelines stratify the recommended age for bioprosthtic valves vs. mechanical valves, and in this context recommend surgical bioprosthetic valves if age > yrs, based on an estimate 50% surgically implanted bioprosthtic valve degeneration at approximately 15yrs or more. IPAC added a committee comment as follows: the longer-term evidence on TAVI is from earlier generation TAVI devices and the technology is evolving. Longer-term evidence is needed and this should be taken into account by the multidisciplinary team. Recently at EuroPCR 2016 a study investigating the long-term durability of transcatheter aortic valve implantation (TAVI) was reported; showing an estimate that the eight-year rate of structural valve degeneration of TAVI bioprosthetic valves was already approximately 50%. The mode of degeneration of TAVI valves also appears to differ to current surgically implanted valves and hence TAVI bioprosthetic valve degeneration should not & cannot be deemed to be similar to surgical bioprosthetic valves. This is important known information that should be included in this report, especially as more intermediate risk patients are now being deemed potential TAVI candidates. 12 of 13
13 23 Consultee 7 Independent consultancy Health Economics & Outcomes Research Sec Comments Response 6.4 RCT follow up has only been reported for 5 years but TAVI data is available for 10 years from commercial devices and 15 years since the earliest patient implants. This data is not available for all devices though, reinforcing the need to allow clinical decision making to take priority when deciding if, to perform a TAVI, and which device to use. Thank you for your comments. IPAC added a committee comment as follows : There is a need for longer-term evidence and this should be taken into account by the multidisciplinary team. Longer-term evidence is needed and this should be taken into account by the multidisciplinary team. "Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees." 13 of 13
Interventional procedures guidance Published: 26 July 2017 nice.org.uk/guidance/ipg586
Transcatheter aortic valve implantation for aortic stenosis Interventional procedures guidance Published: 26 July 17 nice.org.uk/guidance/ipg586 Your responsibility This guidance represents the view of
Transcatheter aortic valve implantation for aortic stenosis
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Transcatheter aortic valve implantation for aortic stenosis Aortic stenosis occurs when the aortic valve
Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504
Transcatheter valve-in-valve e implantation for aortic bioprosthetic valve dysfunction Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504 Your responsibility This
National Institute for Health and Care Excellence IP865/2 Sutureless Aortic Valve Replacement for aortic stenosis
National Institute for Health and Care Excellence IP865/2 Sutureless Aortic Valve Replacement for aortic stenosis IPAC 14/06/18: 1 1 NHS professional 2 1 NHS professional ments 1.1 1.1 Current evidence
Policy Specific Section: March 30, 2012 March 7, 2013
Medical Policy Transcatheter Aortic Valve Replacement for Aortic Stenosis Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date:
What is TAVR? Transcatheter Aortic Valve Replacement
What is TAVR? Transcatheter Aortic Valve Replacement What Are Your Options for Treating Severe Aortic Stenosis? Treatment for aortic stenosis depends on how far your disease has progressed. If your stenosis
Assessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University
Assessment and Preparation of Patients with TAVI Rob Tanzola Associate Professor, Queen s University My patient has aortic stenosis and needs non-cardiac surgery Should (s)he get a TAVI? Rob Tanzola Associate
A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
Clinical Commissioning Policy: Transcatheter Aortic Valve Implantation (TAVI) For Aortic Stenosis. December Reference : NHSCB/A10/a/1
Clinical Commissioning Policy: Transcatheter Aortic Valve Implantation (TAVI) For Aortic Stenosis December 2012 Reference : NHSCB/A10/a/1 NHS Commissioning Board Clinical Commissioning Policy: Transcatheter
Summary Transcatheter aortic valve implantation: Evaluation of the evidence and synthesis of organizational issues
ETMIS 2012 ; Vol. 8 : N 0 8 Summary Transcatheter aortic valve implantation: Evaluation of the evidence and synthesis of organizational issues May 2012 A production of the Institut national d excellence
Trans-catheter aortic valve implantation (TAVI) work up
Trans-catheter aortic valve implantation (TAVI) work up You have been referred for an assessment known as a TAVI work up because you have been diagnosed with aortic stenosis. This factsheet explains the
Transcatheter Aortic Valve Implantation Procedure (TAVI)
Page 1 of 5 Procedure (TAVI) Introduction Aortic stenosis (AS) is a common heart valve problem associated with heart failure and death. Surgical valve repair or replacement is recommended if AS patients
Transcatheter Aortic Valve Implantation (TAVI) Overview for Wales. Dr Richard Anderson University Hospital of Wales, Cardiff, UK
Transcatheter Aortic Valve Implantation (TAVI) Overview for Wales Dr Richard Anderson University Hospital of Wales, Cardiff, UK Aortic stenosis is a disease of old age Age demographics in Wales % Wales
THE VALVE CLINIC VALVE CONFERENCE
VALVE CLINIC THE VALVE CLINIC Houston Methodist DeBakey Valve Clinic combines outstanding clinical care, advanced imaging and surgical excellence to offer coordinated evaluation and treatment options for
Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
O P E N A C C E S S Department of Cardiology, Aswan Heart Centre *Email: ahmed.elguindy@aswanheartcentre.com Lessons from the trials PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients Ahmed ElGuindy*
Aortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
Percutaneous Management of Severe AS in Octagenarians. Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington
Percutaneous Management of Severe AS in Octagenarians Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington May 2017 Outline Aetiology of AS Natural History of AS Assessment
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
TAVR and Cardiac Surgeons
TAVR and Cardiac Surgeons TAVR and Cardiac Surgeons Ragheb Hasan Consultant and Clinical Lead Cardiothoracic Surgeon Manchester Royal Infirmary, Oxford Road, Manchester UK Aortic Stenosis Is A Growing
Percutaneous Therapy for Calcific Mitral Valve Disease
31 st Annual State of the Art Echocardiography San Diego, CA February 18, 2018 5:00 5:15 PM 15 min Percutaneous Therapy for Calcific Mitral Valve Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive
Transcatheter Aortic Valve Replacement TAVR
Transcatheter Aortic Valve Replacement TAVR Paul Gordon, MD Associate Prof of Medicine, Brown University Director, Cardiac Catheterization Laboratory The Miriam Hospital Disclosures: none 100 Symptomatic
Transcatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 6/2018 Origination: 2/2012 Next Review: 2/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison
Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Mauri, V. et al.: Circ Cardiovasc Interv. 2017;10:e005013 All trademarks are the property
Alternate Vascular Access for TAVR. Gian Paolo Ussia Campus Bio-medico University, Rome Italy
Alternate Vascular Access for TAVR Gian Paolo Ussia Campus Bio-medico University, Rome Italy g.ussia@unicampus.it REQUIRED Gian Paolo Ussia I have no relevant financial relationships Transcatheter Valves
Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial
Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Transcatheter Aortic Valve Implantation for Aortic Stenosis Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Transcatheter Aortic Valve Implantation
Less Invasive Aortic Valve Surgery
Less Invasive Aortic Valve Surgery SCTS Brighton 19th March 2013 Andrew Chukwuemeka MD FRCS Consultant Cardiothoracic Surgeon Hammersmith Hospital Imperial College Healthcare NHS Trust Less Invasive Aortic
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
Transcatheter aortic valve implantation and pre-procedural risk assesment
Transcatheter aortic valve implantation and pre-procedural risk assesment Alec Vahanian,FESC, FRCP(Edin.) Bichat Hospital University Paris VII, Paris, France Disclosures Relationship with companies who
Transcatheter aortic valve replacement is considered investigational for all other indications.
Medical Policy Original Policy Date: March 30, 2012 Effective Date: July 1, 2018 Section: 7.0 Surgery Page: Page 1 of 33 Policy Statement Transcatheter aortic valve replacement with an U.S. Food and Drug
A COMMISSIONING FRAMEWORK FOR TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) FOR SEVERE SYMPTOMATIC AORTIC STENOSIS
A COMMISSIONING FRAMEWORK FOR TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) FOR SEVERE SYMPTOMATIC AORTIC STENOSIS Dr Su Sethi, Consultant in Public Health Medicine, North West Specialised Commissioning
RANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING
AORTIC VALVE DISEASE RANDOMISED TRIALS COMPARING TAVI WITH SAVR STEPHAN WINDECKER DEPARTMENT OF CARDIOLOGY SWISS CARDIOVASCULAR CENTER AND CLINICAL TRIALS UNIT BERN BERN UNIVERSITY HOSPITAL, SWITZERLAND
Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update
Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder
Transcatheter Aortic Valve Implantation Anaesthetic Prespectives
Transcatheter Aortic Valve Implantation Anaesthetic Prespectives Dr Simon Chan Consultant Department of Anaesthesia and Intensive Care Prince of Wales Hospital Hong Kong 11 Oct 2014 Aortic Stenosis Prevalence
Transcatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 2/2019 Origination: 2/2012 Next Review: 2/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of transcatheter aortic valve implantation for aortic stenosis Aortic stenosis occurs
Indication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
Update on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
Patient selection for transcatheter aortic valve implantation (TAVI) in South Africa
COMMENTARY Patient selection for transcatheter aortic valve implantation (TAVI) in South Africa Martyn Thomas * and Thomas A. Mabin # * Guys and St Thomas Hospital, London, United Kingdom # Vergelegen
Vinod H. Thourani, MD, FACC, FACS
Considering SAVR in the TAVR era: Surgical Implications of TAVR Vinod H. Thourani, MD, FACC, FACS Professor of Cardiothoracic Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown
Aortic Valve Stenosis and TAVR: Putting it all together.
Aortic Valve Stenosis and TAVR: Putting it all together. Maria L. Held, MSN CNS Valve Clinic Coordinator at The Cleveland Clinic Alliance of Cardiovascular Professionals April 14 th, 2018 Brief Anatomy
Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of transcatheter aortic valve implantation for aortic stenosis Aortic stenosis occurs
How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, 2016 11:00 11:25 PM 25 min 1 M U H A M E D S A R I Ć, M D, P H D
Transcatheter Aortic Valve Replacement (TAVR)
UW MEDICINE PATIENT EDUCATION Transcatheter Aortic Valve Replacement (TAVR) Treatment for aortic stenosis This handout explains when your doctor may advise TAVR to treat aortic stenosis. It includes the
TAVR for low-risk patients in 2017: not so fast.
TAVR for low-risk patients in 2017: not so fast. Enrico Ferrari, MD, FETCS Cardiac Surgery Department Cardiocentro Ticino Foundation Lugano, Switzerland Conflicts of Interest Consultant and proctor for
Objectives. Describe a multidisciplinary team and it s utilization in the inpatient cardiovascular surgical patient
None Endorsements Objectives Describe a multidisciplinary team and it s utilization in the inpatient cardiovascular surgical patient Understand clinical and clinician benefits of a multidisciplinary team
TAVR in 2017 What we know? What to expect?
Journal of Geriatric Cardiology (2018) 15: 55 60 2018 JGC All rights reserved; www.jgc301.com Perspective Open Access TAVR in 2017 What we know? What to expect? Panagiota Kourkoveli 1,*, Konstantinos Spargias
Is it a business for the cardiac surgeon?
TAVI FOR LOW RISK PATIENTS Is it a business for the cardiac surgeon? Augusto D Onofrio Gino Gerosa Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Italy T A V I Cardiac surgery
evidence note Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults who are not eligible for surgery
evidence note Update of evidence note 38 Number 51 June 2014 Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults who are not eligible for surgery What is an
ACCESS TO ALL APPROPRIATE TREATMENTS FOR ALL HEART VALVE DISEASE PATIENTS
ACCESS TO ALL APPROPRIATE TREATMENTS FOR ALL HEART VALVE DISEASE PATIENTS ~2.9 TO 5.8 MILLION ADULTS IN THE U.S. HAVE AORTIC VALVE DISEASE If left untreated, heart valve disease can be fatal Medicare patients
Successful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement
Advanced Studies in Medical Sciences, Vol. 2, 2014, no. 1, 37-45 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/asms.2014.31213 Successful Transfemoral Edwards Sapien Aortic Valve Implantation
TAVR SPRING 2017 The evolution of TAVR
TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility
Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
Transcatheter Aortic Valve Implantation:
Transcatheter Aortic Valve Implantation: Information for Patients and Families FD.635.D356.PHC (R.May-18) cover1 Transcatheter Aortic Valve Implantation: Information for Patients and Families Previously
Heart Team For TAVI Who and How?
2 nd TAVI Summit 2012, Seoul Corea Heart Team For TAVI Who and How? Alain Cribier, MD, Charles Nicolle Hospital University of Rouen, France Disclosure Edwards Lifesciences Consultant Training / proctoring
Transcatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
Masterclass III Advances in cardiac intervention. Percutaneous valvular intervention a novel approach
Masterclass III Advances in cardiac intervention Percutaneous valvular intervention a novel approach Professor Roger Boyle CBE National Director for Heart Disease and Stroke London Medical therapy Medical
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
Cardiac Valve/Structural Therapies
Property of Dr. Chad Rammohan Cardiac Valve/Structural Therapies Chad Rammohan, MD FACC Medical Director, El Camino Hospital Cardiac Catheterization Lab Director, Interventional and Structural Cardiology,
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
What is TAVR? Transcatheter Aortic Valve Replacement
What is TAVR? Transcatheter Aortic Valve Replacement What Are Your Options for Treating Severe Aortic Stenosis? Treatment for aortic stenosis depends on how far your disease has progressed. If your stenosis
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
The Future of Medicine. Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy
The Future of Medicine Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy FIRST PATIENT TO UNDERGO PTCA FIRST PATIENT TO UNDERGO TAVI Grüntzig
TAVR: Intermediate Risk Patients
TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University
3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong
3 years after introduction of TAVI in QEH Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong HA Convention 2014 Introduction Aortic Stenosis most common valvular heart disease
Transforming the Treatment of Aortic Valve Disease
Transforming the Treatment of Aortic Valve Disease How Do Your Heart Valves Work? Pulmonary Valve Has three leaflets. It controls blood flow from the right ventricle to the pulmonary artery, sending blood
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves Trial II
Department of Medicine Director, Transcatheter Aortic Valve Program June 2013 [First Name] [Last Name], [Suffix] [Hospital or Practice Name] [Address] [City], [State] [Zip] Dear Dr. [Last name], We are
Transcatheter Aortic Valve Implantation (TAVI) PROOF. Patient Information leaflet. Lancashire Cardiac Centre
Transcatheter Aortic Valve Implantation (TAVI) Patient Information leaflet Lancashire Cardiac Centre Welcome to the Lancashire Cardiac Centre During your admission you will be admitted to Ward 37. Ward
Next Generation Therapies: Aortic, Mitral and Beyond
Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017 Next Generation Therapies:
Transcatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: Original Effective Date: MM.06.019 10/01/2012 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/27/2018
Trans Catheter Aortic Valve Replacement
Trans Catheter Aortic Valve Replacement Satish K Surabhi, MD,FACC,FSCAI Medical Director, Cardiac Cath Labs AnMed Health Heart and Vascular Care No financial conflict of interest related to this talk Will
Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS
Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T h e Pa
Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS
Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T H E P A R T N E R T R
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France
Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France Faculty disclosure Bernard Iung I disclose the following financial relationships: Consultant
7 th Conference of Transcatheter Heart Valve Therapies
7 th Conference of Transcatheter Heart Valve Therapies May 18-19, 2018, Athens Hilton Athens, Greece Course Directors Stratis Pattakos MD Konstantinos Spargias MD Panos Vardas MD Co-Directors Nick Bouboulis
Transcatheter Heart Valve. Replacement. With the Edwards SAPIEN 3. for Patients & Caregivers
For Patients With a Failing Surgical Bioprosthetic Heart Valve Transcatheter Heart Valve Replacement With the Edwards SAPIEN 3 Transcatheter Heart Valve for Patients & Caregivers This patient booklet is
National Institute for Health and Clinical Excellence
National Institute for Health and Clinical Excellence 319 Deep brain stimulation for tremor and dystonia (excluding Parkinson s disease) nts table IPAC date: 16 June 2006 Consultee name nts The Dystonia
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
Transcatheter Aortic Valve Replacement
INTERMEDIATE OR GREATER RISK Transcatheter Aortic Valve Replacement with the Edwards SAPIEN 3 Transcatheter Heart Valve For Patients & Caregivers This patient booklet is for those who are suffering from
Transcatheter Heart Valve Therapy
Edwards Lifesciences 2017 Investor Conference Transcatheter Heart Valve Therapy Larry L. Wood Corporate Vice President, Transcatheter Heart Valves Leader in ~$3B Global Transcatheter Heart Valves Primary
Optimal Imaging Technique Prior to TAVI -Echocardiography-
2014 KSC meeting Optimal Imaging Technique Prior to TAVI -Echocardiography- Geu-Ru Hong, M.D. Ph D Associate Professor of Medicine Division of Cardiology, Severance Cardiovascular Hospital Yonsei University
Transcatheter Aortic Valve Implantation (TAVI)
Transcatheter Aortic Valve Implantation (TAVI) QEH Registry A Multidisciplinary Team Approach Michael KY Lee 1, LK Chan 1, KC Chan 1, KT Chan 1, SF Chui 1, HS Ma 1, CY Wong 1, CS Chiang 1, P Li 1, CB Lam
Transcatheter Aortic Valve Replacement. Larry L. Wood Corporate Vice President
Transcatheter Aortic Valve Replacement Larry L. Wood Corporate Vice President Leader in ~$3.5B Global Transcatheter Aortic Valve Replacement Market Primary global growth drivers: indication expansion,
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
THE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON
THE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON INTRODUCTION History of heart valve intervention Current indications
The Impact of TAVI Nurse Coordinator on patient management of Transcatheter Aortic Valve Implantation (TAVI) program in QEH
HA Convention 18-19 May 2015 The Impact of TAVI Nurse Coordinator on patient management of Transcatheter Aortic Valve Implantation (TAVI) program in QEH Division of Cardiology Department of Medicine Queen
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
Are Heart Valve Referral Centers Feasible in Latin America?
Are Heart Valve Referral Centers Feasible in Latin America? Vadim Kotowicz, MD Chief of Cardiovascular Surgery Department Italian Hospital of Buenos Aires Disclosure Medtronic inc. Consultanting Johnson
Aortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC No Financial Disclosures Aortic Stenosis AS is an insidious disease with a long latency period followed by